A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of SIBP's MMR Vaccine Compared to GSK MMR Vaccine in Children, 9-11 Months of Age
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Measles, mumps and rubella combined vaccine-Shanghai Institute Of Biological Products (Primary)
- Indications Measles
- Focus Therapeutic Use
Most Recent Events
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.
- 08 May 2024 New trial record